

RADIOPHARM APPOINTS DR. LEILA ALLAND AS NON-EXECUTIVE DIRECTOR

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr. Leila Alland to its Board as a Non-Executive Director.

Dr. Alland is a pediatric hematologist-oncologist with a strong track record in developing oncology drug products. Over the course of her career, Dr. Alland has held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to multiple successful drug approvals.

Dr. Alland is currently Chief Medical Officer of PMV Pharmaceuticals, a clinical stage precision oncology company. She serves on the Boards of several biopharmaceutical companies and is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research. Previously, she served as Chief Medical Officer of Affimed, a clinical stage immuno-oncology company.

Dr. Alland obtained her medical degree from New York University School of Medicine, completed her post-doctoral training in pediatrics and hematology/oncology at The Children's Hospital of Philadelphia, The New York Hospital and Memorial Sloan-Kettering Cancer Center, and served as assistant professor of pediatrics at Albert Einstein College of Medicine. During her academic tenure, she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders.

Radiopharm's CEO & Managing Director Riccardo Canevari said: “Dr. Alland's scientific and clinical expertise along with her impressive background in pharmaceutical drug development make her a valuable addition to our Board of Directors as we steer Radiopharm through a pivotal period of innovation and growth.”

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

ASX ANNOUNCEMENT
6 JUNE 2022



Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>